Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Annette Hood"'
Autor:
Maura Harrigan, Courtney McGowan, Annette Hood, Leah M. Ferrucci, ThaiHien Nguyen, Brenda Cartmel, Fang-Yong Li, Melinda L. Irwin, Tara Sanft
Publikováno v:
Nutrients, Vol 13, Iss 11, p 3730 (2021)
The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary supplements should not be used for cancer
Externí odkaz:
https://doaj.org/article/6047a53df20342239f733b7280464583
Autor:
Annette Hood, Blerina Mukallari, Jacqueline Majeski, Lajos Pusztai, Kerin Adelson, Kejal Amin
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:BPI23-012
Autor:
Lajos Pusztai, Shi-Yi Wang, Kerin B. Adelson, Annette Hood, Natalia Kunst, Michael P. DiGiovanna, Sarah S. Mougalian
Publikováno v:
Cancer Research. 80:PD10-05
Background: Several neoadjuvant and adjuvant treatment options exist for patients with HER2-positive (HER2+) stage II-III breast cancer. Recent results of the KATHERINE trial (NCT01772472) showed that adjuvant T-DM1 can reduce distant recurrence risk
Publikováno v:
Annals of Pharmacotherapy. :106002802211491
Background: Real-world data regarding the use of poly (ADP-ribose) polymerase (PARP) inhibitors in recurrent ovarian cancer patients with non-BRCA homologous recombination (HR) mutations or somatic BRCA mutations are lacking. Objective: The purpose o
Autor:
Rachel, Jaber Chehayeb, Annette, Hood, Xiaoliang, Wang, Rebecca, Miksad, Sarah, Schellhorn Mougalian, Maryam B, Lustberg, Shi-Yi, Wang, Rachel A, Greenup, Lajos, Pusztai, Natalia, Kunst
Publikováno v:
JAMA Network Open. 5:e2244204
ImportanceAdvances in treatment of metastatic breast cancer (MBC) led to changes in clinical practice and treatment costs in the US over the past decade. There is limited information on current MBC treatment sequences and associated costs by MBC subt
Autor:
Annette Hood, Tara Sanft, Maura Harrigan, ThaiHien Nguyen, Brenda Cartmel, Courtney McGowan, Fangyong Li, Leah M. Ferrucci, Melinda L. Irwin
Publikováno v:
Nutrients
Volume 13
Issue 11
Nutrients, Vol 13, Iss 3730, p 3730 (2021)
Volume 13
Issue 11
Nutrients, Vol 13, Iss 3730, p 3730 (2021)
The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary supplements should not be used for cancer
Autor:
Kerin B. Adelson, Natalia Kunst, Michael P. DiGiovanna, Lajos Pusztai, Shi-Yi Wang, Annette Hood, Sarah S. Mougalian
Publikováno v:
JAMA Network Open
This economic evaluation modeled the cost-effectiveness of 5 neoadjuvant-adjuvant treatment strategies for women with ERBB2-positive breast cancer.
Key Points Question What is the cost-effective neoadjuvant-adjuvant treatment strategy among seve
Key Points Question What is the cost-effective neoadjuvant-adjuvant treatment strategy among seve
Autor:
Annette Hood, ThaiHien Nguyen, Melinda L. Irwin, Fangyong Li, Tara Sanft, Brenda Cartmel, Courtney McGowan, Leah M. Ferrucci, Maura Harrigan
Publikováno v:
Cancer Research. 81:PS8-09
Background: Dietary supplements (DS), defined as herbal preparations, vitamins and minerals (DSHEA Act 1994), are used by 70% of cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research 2018 Cancer Prevention Recommenda
Autor:
Lajos Pusztai, Hannah Dzimitrowicz, Vicente Valero, Debu Tripathy, Akshara Singareeka Raghavendra, Michael Berger, Rashmi Krishna Murthy, Annette Hood, Christos Hatzis, Craig A. Vargo, Osama Abdelghany
Publikováno v:
Journal of Clinical Oncology. 34:3511-3517
Purpose Ado-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)–positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane. However, there
Publikováno v:
Journal of Oncology Pharmacy Practice. 23:491-495
Purpose To evaluate and compare the rate of hypersensitivity reactions between two low-dose steroid pre-medication regimens for paclitaxel-based treatments. Methods This was a single-center, retrospective, descriptive study, comparing the incidence o